Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

AI may provide an answer to the question of whether drugs initially developed and prescribed for non-neurodegenerative physical conditions can be used to treat individuals with Parkinson’s disease.

AbbVie ABBV continues to build momentum with its oncology franchise, with the recent FDA approval for Emrelis. This ...

Bayer said it received approval from the Food and Drug Administration for its drug Nubeqa, which treats patients with a certain type of prostate cancer.

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.